# Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer

Source: https://onco.cc/trials/nct07081360/  
OnCo record `nct07081360` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in pancreatic cancer, run by Minia University, now recruiting.

## Summary

Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer is a phase 3, randomised interventional study registered as NCT07081360 by Minia University, with a registry enrolment figure of 262 participants, started 2025-07-20 and due to reach its primary completion in 2028-07-20. Interventions recorded: Neoadjuvant chemotherapy; Upfront Surgery Group. Conditions listed: Pancreas Cancer; Periampullary Cancer; Periampullary Carcinoma Resectable; Pancreatic Cancer Resectable; Ampullary Cancer; Pancreas Adenocarcinoma. Primary outcome: Overall survival rate. Pancreatic eligibility wording from the registry: "* Histologically or cytologically confirmed pancreatic head cancer or periampullary carcinoma(endoscopic ultrasound (EUS)-guided biopsy)". Sites: Egypt. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07081360
- Phase: 3
- Setting: Neoadjuvant Chemotherapy Followed by Surgery Versus Upfront Surgery for Clearly Resectable Pancreatic Head Cancer and Periampullary Cancer: A Randomized Controlled Trial
- Sponsor: Minia University
- Enrolled: 262

## Sources

- ClinicalTrials.gov NCT07081360: https://clinicaltrials.gov/study/NCT07081360

## Connected records

- cancers: [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07081360.json